Results for: Royalty Pharma

Royalty Pharma, a leading biopharmaceutical royalty company, is set to release its quarterly earnings on Wednesday, November 6th. Analysts anticipate an EPS of $0.93, and investors are keen to see if the company surpasses expectations and provides positive guidance. This article delves into Royalty Pharma’s past performance, analyst insights, and peer comparisons, providing a comprehensive overview of key factors influencing the upcoming earnings release.

In a recent episode of CNBC’s ‘Mad Money Lightning Round,’ Jim Cramer shared his thoughts on several stocks, including Ally Financial, Snowflake, Royalty Pharma, and Core Scientific. Cramer recommended buying Ally Financial but was hesitant on Snowflake due to recent downgrades. He expressed disappointment with Royalty Pharma’s performance and labeled Core Scientific as overvalued.